197. Rapisuwon S., Parks K., Al-Refaie W., Atkins M. B. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report // Melanoma Res. ‒ 2014. ‒ T. 24, № 5. ‒ C. 509-11.
198. Zebary A., Omholt K., Vassilaki I., Hoiom V., Linden D., Viberg L., Kanter-Lewensohn L., Johansson C. H., Hansson J. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma // J Dermatol Sci. ‒ 2013. ‒ T. 72, № 3. ‒ C. 284-9.
199. Hodi F. S., Corless C. L., Giobbie-Hurder A., Fletcher J. A., Zhu M., Marino-Enriquez A., Friedlander P., Gonzalez R., Weber J. S., Gajewski T. F., O'Day S. J., Kim K. B., Lawrence D., Flaherty K. T., Luke J. J., Collichio F. A., Ernstoff M. S., Heinrich M. C., Beadling C., Zukotynski K. A., Yap J. T., Van den Abbeele A. D., Demetri G. D., Fisher D. E. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin // J Clin Oncol. ‒ 2013. ‒ T. 31, № 26. ‒ C. 3182-90.
200. Kim K. B., Eton O., Davis D. W., Frazier M. L., McConkey D. J., Diwan A. H., Papadopoulos N. E., Bedikian A. Y., Camacho L. H., Ross M. I., Cormier J. N., Gershenwald J. E., Lee J. E., Mansfield P. F., Billings L. A., Ng C. S., Charnsangavej C., Bar-Eli M., Johnson M. M., Murgo A. J., Prieto V. G. Phase II trial of imatinib mesylate in patients with metastatic melanoma // Br J Cancer. ‒ 2008. ‒ T. 99, № 5. ‒ C. 734-40.
201. Kalinsky K., Lee S., Rubin K. M., Lawrence D. P., Iafrarte A. J., Borger D. R., Margolin K. A., Leitao M. M., Jr., Tarhini A. A., Koon H. B., Pecora A. L., Jaslowski A. J., Cohen G. I., Kuzel T. M., Lao C. D., Kirkwood J. M. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607) // Cancer. ‒ 2017. ‒ T. 123, № 14. ‒ C. 2688-2697.
202. Guo J., Carvajal R. D., Dummer R., Hauschild A., Daud A., Bastian B. C., Markovic S. N., Queirolo P., Arance A., Berking C., Camargo V., Herchenhorn D., Petrella T. M., Schadendorf D., Sharfman W., Testori A., Novick S., Hertle S., Nourry C., Chen Q., Hodi F. S. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial // Ann Oncol. ‒ 2017. ‒ T. 28, № 6. ‒ C. 1380-1387.
203. Guo J., Si L., Kong Y., Flaherty K. T., Xu X., Zhu Y., Corless C. L., Li L., Li H., Sheng X., Cui C., Chi Z., Li S., Han M., Mao L., Lin X., Du N., Zhang X., Li J., Wang B., Qin S. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification // J Clin Oncol. ‒ 2011. ‒ T. 29, № 21. ‒ C. 2904-9.
204. Garcia-Casado Z., Millan-Esteban D., Manrique-Silva E., Requena C., Traves V., Nagore E. Germline cancer-related mutations detected by routine targeted NGS for tumour analysis: A series of 357 melanoma patients // J Eur Acad Dermatol Venereol. ‒ 2023. ‒ T. 37, № 12. ‒ C. e1384-e1387.
205. Reiman A., Kikuchi H., Scocchia D., Smith P., Tsang Y. W., Snead D., Cree I. A. Validation of an NGS mutation detection panel for melanoma // BMC Cancer. ‒ 2017. ‒ T. 17, № 1. ‒ C. 150.
206. Zhu M. L., Zhou L., Sadri N. Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma // Virchows Arch. ‒ 2018. ‒ T. 473, № 3. ‒ C. 371-377.
207. Heinzerling L., Kuhnapfel S., Meckbach D., Baiter M., Kaempgen E., Keikavoussi P., Schuler G., Agaimy A., Bauer J., Hartmann A., Kiesewetter F., Schneider-Stock R. Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice // Br J Cancer. ‒ 2013. ‒ T. 108, № 10. ‒ C. 2164-71.
208. Kong Y., Krauthammer M., Halaban R. Rare SF3B1 R625 mutations in cutaneous melanoma // Melanoma Res. ‒ 2014. ‒ T. 24, № 4. ‒ C. 332-4.
209. Lukowsky A., Schafer-Hesterberg G., Sterry W., Voit C. Germline CDKN2A/p16 mutations are rare in multiple primary and familial malignant melanoma in German patients // J Dermatol Sci. ‒ 2008. ‒ T. 49, № 2. ‒ C. 163-5.
210. Menzer C., Menzies A. M., Carlino M. S., Reijers I., Groen E. J., Eigentler T., de Groot J. W. B., van der Veldt A. A. M., Johnson D. B., Meiss F., Schlaak M., Schilling B., Westgeest H. M., Gutzmer R., Pfohler C., Meier F., Zimmer L., Suijkerbuijk K. P. M., Haalck T., Thoms K. M., Herbschleb K., Leichsenring J., Menzer A., Kopp-Schneider A., Long G. V., Kefford R., Enk A., Blank C. U., Hassel J. C. Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations // J Clin Oncol. ‒ 2019. ‒ T. 37, № 33. ‒ C. 3142-3151.
211. Omholt K., Krockel D., Ringborg U., Hansson J. Mutations of PIK3CA are rare in cutaneous melanoma // Melanoma Res. ‒ 2006. ‒ T. 16, № 2. ‒ C. 197-200.
212. Rogiers A., Vander Borght S., Tuand K., Wolter P., Stas M., Boecxstaens V., Garmyn M., van den Oord J. J., Vandenberghe P., Bechter O. Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE // Melanoma Res. ‒ 2017. ‒ T. 27, № 5. ‒ C. 507-510.
213. Yan C., Zhao C., Yang K., Zhou H., Jing L., Zhao W., Dou W., Xia Q., Ma J., Wei B., Guo Y. Rare c-KIT c.1926delA and c.1936T>G Mutations in Exon 13 Define Imatinib Resistance in Gastrointestinal Stromal Tumors and Melanoma Patients: Case Reports and Cell Experiments // Front Mol Biosci. ‒ 2022. ‒ T. 9. ‒ C. 730213.
214. Chisholm J. C., Suvada J., Dunkel I. J., Casanova M., Zhang W., Ritchie N., Choi Y., Park J., Das Thakur M., Simko S., Wan Rachel Tam N., Ferrari A. BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma // Pediatr Blood Cancer. ‒ 2018. ‒ T. 65, № 5. ‒ C. e26947.